SEC Form 4 · accession 0001778623-26-000005
Dianthus Therapeutics, Inc. /DE/ · DNTH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Adam M Veness
Officer — SVP, General Counsel and Sec.
Period of report
Jun 17, 2026
Accepted (ET)
Jun 18, 2026 · 4:30 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001690585
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 17, 2026 | M | 30,000 | $17.88 | A | 30,000 | D | |
| Common StockF2 | Jun 17, 2026 | S | 16,771 | $80.34 | D | 13,229 | D | |
| Common StockF3 | Jun 17, 2026 | S | 13,229 | $81.38 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $17.88 | Jun 17, 2026 | M | 30,000 | D | — | Jan 23, 2034 | Common Stock | 30,000 | 80,000 | D |
Explanation of responses
- F1The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026.
- F2The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $80.00 to $80.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $81.00 to $81.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.